DSC Investment logo

DSC Investment

Asia, Seoul-t'ukpyolsi, South Korea, Seoul

Description

DSC Investment is a prominent venture capital firm based in Seoul, South Korea, established in 2009. As a publicly listed company on the KOSDAQ stock exchange (stock code 241520), it holds a significant and transparent position within the Korean venture ecosystem. The firm is recognized for its strategic investments in early-stage and growth companies, playing a crucial role in fostering innovation across various high-growth sectors. DSC Investment has built a strong reputation for identifying and nurturing promising startups, contributing significantly to their scaling and market penetration.

The firm's investment strategy primarily targets companies in the IT, software, biotechnology, and new materials sectors. DSC Investment typically engages in seed, Series A, and Series B funding rounds, though it also participates in later-stage growth equity. Their approach involves not just capital injection but also providing strategic guidance and leveraging their extensive network to support portfolio companies. They seek out startups with strong technological foundations, innovative business models, and high growth potential, aiming to create long-term value.

With assets under management (AUM) approaching ₩1 trillion (approximately $750 million USD), DSC Investment manages a diverse portfolio of over 20 venture funds. These funds are strategically deployed to support a wide array of startups, from nascent ideas to established growth companies. Notable investments include leading companies in the AI healthcare and biotech space, such as Lunit and VUNO, demonstrating their capability to back market leaders. Their commitment to fostering a vibrant startup ecosystem is evident through their consistent investment activity and their role in numerous successful exits.

DSC Investment's robust financial standing and deep industry expertise make it a key player in the South Korean venture capital landscape. Their focus on early-stage innovation, combined with their capacity for substantial follow-on investments, positions them as a preferred partner for ambitious entrepreneurs. The firm continues to be a driving force behind technological advancement and economic growth in South Korea, consistently seeking out the next generation of disruptive companies.

Investor Profile

DSC Investment has backed more than 61 startups, with 16 new investments in the last 12 months alone. The firm has led 9 rounds, about 15% of its total and boasts 10 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Seed, Series B rounds (top funding stages).
  • Majority of deals are located in South Korea, United States, Israel.
  • Strong thematic focus on Artificial Intelligence (AI), Health Care, Biotechnology.
  • Led 7 rounds in the past year.
  • Typical check size: $500K – $7M.

Stage Focus

  • Series A (33%)
  • Seed (28%)
  • Series B (25%)
  • Series C (8%)
  • Series Unknown (5%)
  • Secondary Market (2%)

Country Focus

  • South Korea (70%)
  • United States (25%)
  • Israel (3%)

Industry Focus

  • Artificial Intelligence (Ai)
  • Health Care
  • Biotechnology
  • E-commerce
  • Software
  • Manufacturing
  • Machine Learning
  • Medical
  • Medical Device
  • Information Technology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does DSC Investment frequently co-invest with?

Industrial Bank of Korea
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 4
Schmidt
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 14
Smilegate Investment
Asia, Kyonggi-do, South Korea, Seongnam
Co-Investments: 5
Mirae Asset Venture Investment
Asia, Kyonggi-do, South Korea, Seongnam
Co-Investments: 5
Korea Investment Partners
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 9
Big Basin Capital
North America, California, United States, Cupertino
Co-Investments: 8
Coolidge Corner Investment
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 4
InterVest Co.
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 7
Premier Partners
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 5
Atinum Partners
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 4

Which angels does DSC Investment often collaborate with?

PF
North America, Massachusetts, United States, Boston
Shared Deals: 1
Zohar Zisapel
Asia, Tel Aviv, Israel, Tel Aviv
Shared Deals: 1

What are some of recent deals done by DSC Investment?

Clobe AI

Chongnoong Dong, Seoul-t'ukpyolsi, South Korea

Clobe AI employs a robust security framework to ensure the secure handling of sensitive financial data.

FinTechSaaSSecurity
SeedMar 11, 2026
Amount Raised: $9,073,427
Clobe ai

Chongnoong Dong, Seoul-t'ukpyolsi, South Korea

Clobe ai is an AI‑powered financial platform that simplifies money management for individuals and small‑to‑medium businesses.

SeedMar 11, 2026
Amount Raised: $9,073,427
Ark

Busan, Pusan-jikhalsi, South Korea

Ark is an AI-based early screening company for chronic disease complications, develops and supplies medical AI solutions.

Series AMar 5, 2026
Amount Raised: $13,507,946
BreezeBio

South San Francisco, California, United States

BreezeBio is a biotechnology business that creates genetic therapies using precision, non-viral delivery across clinically important tissues

BiotechnologyGeneticsPharmaceuticalTherapeutics
Series BFeb 25, 2026
Amount Raised: $60,000,000
Orum Therapeutics

Daejeon, Taejon-jikhalsi, South Korea

Private biotech company creating cell penetrating therapeutic antibodies

BiotechnologyHealth CareTherapeutics
Post Ipo EquityDec 18, 2025
Amount Raised: $98,281,097
arcreal

Seoul, Seoul-t'ukpyolsi, South Korea

arcreal is a digital healthcare company that provides different technologies in the dental industry.

DentalSoftware
SeedDec 16, 2025
Amount Raised: $5,422,785
Pharos iBio Co.

Anyang, Kyonggi-do, South Korea

Pharos iBio Co. specializing in drug development that develops treatments for intractable diseases.

BiotechnologyHealth CareInformation Technology
Post Ipo DebtDec 4, 2025
Amount Raised: $12,917,990
PineTree Therapeutics

Cambridge, Massachusetts, United States

PineTree Therapeutics engages in the development of disruptive therapies in Oncology and Immuno-oncology.

BiotechnologyMedicalOncologyTherapeuticsWellness
Series BOct 28, 2025
Amount Raised: $47,000,000
Money Walk

Seoul, Seoul-t'ukpyolsi, South Korea

Money Walk is a novel pedometer program that allows users to earn money simply by walking.

Health CareWellness
Series ASep 2, 2025
Amount Raised: $12,942,810
Nex Eye

Seoul, Seoul-t'ukpyolsi, South Korea

Nex Eye is a start-up that develops first-in-class antibodies targeting refractory factors of immuno-oncology drugs.

MedicalOncologyPharmaceutical
Series BAug 13, 2025
Amount Raised: $44,310,374

Find More Investors Like DSC Investment

Discover similar investors in our database and build your perfect investor list.

Need help with your fundraising strategy?Read our fundraising guides